NeuroOne Medical Technologies (NMTC) Stock Price, News & Analysis

Company Overview

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

Key Stats

• Today's Range: $0.61 to $0.65
• 50-Day Range: $0.43 to $1.08
• 52-Week Range: $0.40 to $1.39
• Volume: 145,814 shs
• Average Volume: 177,066 shs
• Market Capitalization: $29.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.45
• Consensus Rating: Buy

NeuroOne Medical Technologies Stock Analysis - MarketRank™

NeuroOne Medical Technologies scored higher than 43% of companies evaluated by MarketBeat, and ranked 631st out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

NeuroOne Medical Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

NeuroOne Medical Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NeuroOne Medical Technologies is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeuroOne Medical Technologies is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeuroOne Medical Technologies has a P/B Ratio of 6.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.01% of the float of NeuroOne Medical Technologies has been sold short.

Short Interest Ratio / Days to Cover

NeuroOne Medical Technologies has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroOne Medical Technologies has recently increased by 175.44%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroOne Medical Technologies does not currently pay a dividend.

Dividend Growth

NeuroOne Medical Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.01% of the float of NeuroOne Medical Technologies has been sold short.

Short Interest Ratio / Days to Cover

NeuroOne Medical Technologies has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroOne Medical Technologies has recently increased by 175.44%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.25

News Sentiment

NeuroOne Medical Technologies has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for NeuroOne Medical Technologies this week, compared to 1 article on an average week.

Search Interest

Only 2 people have searched for NMTC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added NeuroOne Medical Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, NeuroOne Medical Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $150,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 8.90% of the stock of NeuroOne Medical Technologies is held by insiders.

Percentage Held by Institutions

Only 16.07% of the stock of NeuroOne Medical Technologies is held by institutions.

NMTC Stock Analysis - Frequently Asked Questions

How have NMTC shares performed this year?

NeuroOne Medical Technologies' stock was trading at $0.8259 at the beginning of the year. Since then, NMTC stock has decreased by 24.9% and is now trading at $0.62.
View the best growth stocks for 2025 here.

How were NeuroOne Medical Technologies' earnings last quarter?

NeuroOne Medical Technologies Co. (NASDAQ:NMTC) announced its quarterly earnings results on Wednesday, February, 12th. The company reported $0.06 EPS for the quarter. NeuroOne Medical Technologies had a negative net margin of 82.17% and a negative trailing twelve-month return on equity of 270.70%.
Read the conference call transcript.

Who are NeuroOne Medical Technologies' major shareholders?

NeuroOne Medical Technologies' top institutional shareholders include Cambridge Investment Research Advisors Inc. (0.17%). Insiders that own company stock include Ronald W Mcclurg, Mark Christianson and Christopher Volker.
View institutional ownership trends.

How do I buy shares of NeuroOne Medical Technologies?

Shares of NMTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeuroOne Medical Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroOne Medical Technologies investors own include Schwab US Large-Cap ETF (SCHX), NVIDIA (NVDA), Advanced Micro Devices (AMD), NIO (NIO), Ford Motor (F), Meta Platforms (META) and Plug Power (PLUG).

Company Calendar

• Last Earnings: 2/12/2025
• Today: 5/09/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NMTC
• CIK: 1500198
• Web: www.originalsourcemusic.com
• Phone: (952) 426-1383
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.45
• High Stock Price Target: $1.45
• Low Stock Price Target: $1.45
• Potential Upside/Downside: +133.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-12,320,000.00
• Net Margins: -82.17%
• Pretax Margin: -82.16%
• Return on Equity: -270.70%
• Return on Assets: -129.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.64
• Quick Ratio: 2.41

Sales & Book Value

• Annual Sales: $5.75 million
• Price / Sales: 5.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.10 per share
• Price / Book: 6.20

Miscellaneous

• Outstanding Shares: 47,386,000
• Free Float: 28,116,000
• Market Cap: $29.38 million
• Optionable: Optionable
• Beta: 0.65